A systematic review and meta‐analysis of maintenance treatment for psychotic depression

References

• Jääskeläinen E, Juola T, Korpela H, et al. Epidemiology of psychotic depression – systematic review and meta-analysis. Psychol Med. 2018;48(6):905–918.
   PubMed Web of Science ®Google Scholar
• Lykouras L, Gournellis R. Psychotic (delusional) major depression: new vistas. CPSR. 2009;5(1):1–28.
   Google Scholar
• Parker G, Roy K, Hadzi-Pavlovic D, et al. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord. 1992;24(1):17–24.
   PubMed Web of Science ®Google Scholar
• Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J Ect. 2001;17(4):244–253.
   PubMed Web of Science ®Google Scholar
• Pande AC, Grunhaus LJ, Haskett RF, et al. Electroconvulsive therapy in delusional and non-delusional depressive disorder. J Affect Disord. 1990;19(3):215–219.
   PubMed Web of Science ®Google Scholar
• Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and Meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012;73(04):486–496.
   PubMedGoogle Scholar
• Wijkstra J, Lijmer J, Burger H, et al. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev. 2015;(7):Cd004044.
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Washington (DC): American Psychiatric Association; 2010.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA ,Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Schünemann H, Brożek J, Guyatt G, et al, editors. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group. 2013. Available from guidelinedevelopment.org/handbook
   Google Scholar
• Shiwaku H, Fujita M, Takahashi H. Benzodiazepines reduce relapse and recurrence rates in patients with psychotic depression. JCM. 2020;9(6):1938–1910.
   Google Scholar
• Birkenhager TK, Van Den Broek WW, Mulder PGH, et al. One-year outcome of psychotic depression after successful electroconvulsive therapy. J ECT. 2005;21(4):221–226.
   PubMed Web of Science ®Google Scholar
• Flint AJ, Meyers BS, Rothschild AJ, et al. Effect of continuing olanzapine vs placebo on relapse among patients with psychotic depression in remission: the STOP-PD II randomized clinical trial. JAMA. 2019;322(7):622–631.
   PubMed Web of Science ®Google Scholar
• Meyers BS, Klimstra SA, Gabriele M, et al. Continuation treatment of delusional depression in older adults. Am J Geriatr Psychiatry. 2001;9(4):415–422.
   PubMed Web of Science ®Google Scholar
• Wijkstra J, Burger H, van den Broek WW, et al. Long-term response to successful acute pharmacological treatment of psychotic depression. J Affect Disord. 2010;123(1–3):238–242.
   PubMed Web of Science ®Google Scholar
• Bingham KS, Meyers BS, Mulsant BH, et al. Stabilization treatment of remitted psychotic depression: the STOP-PD study. Acta Psychiatr Scand. 2018;138(3):267–273.
   PubMed Web of Science ®Google Scholar
• Navarro V, Gasto C, Torres X, et al. Continuation/maintenance treatment with nortriptyline versus combined nortriptyline and ECT in late-life psychotic depression: a two-year randomized study. Am J Geriatr Psychiatry. 2008;16(6):498–505.
   PubMed Web of Science ®Google Scholar
• Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009;66(8):838–847.
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Duval SE. How long should patients with psychotic depression stay on the antipsychotic medication? J Clin Psychiatry. 2003;64(4):390–396.
   PubMed Web of Science ®Google Scholar
• Naz B, Craig TJ, Bromet EJ, et al. Remission and relapse after the first hospital admission in psychotic depression: a 4-year naturalistic follow-up. Psychol Med. 2007;37(8):1173–1181.
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Werbeloff N, Mandel FS, et al. Determinants of antidepressant response: Implications for practice and future clinical trials. J Affect Disord. 2018;239:79–84.
   PubMed Web of Science ®Google Scholar
• Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry. 2011;24(1):10–17.
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacol. 2006;31(11):2505–2513.
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Canuso CM, Gharabawi GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry. 2008;16(1):21–30.
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Lam RW, Lepola U, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010;27(10):964–976.
   PubMed Web of Science ®Google Scholar
• Longden E, Read J. Assessing and reporting the adverse effects of antipsychotic medication: a systematic review of clinical studies, and prospective, retrospective, and cross-sectional research. Clin Neuropharmacol. 2016;39(1):29–39.
   PubMed Web of Science ®Google Scholar
• Mainio A, Kuusisto L, Hakko H, et al. Antipsychotics as a method of suicide: population based follow-up study of suicide in Northern Finland. Nord J Psychiatry. 2021;75(4):281–285.
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004;24(4):365–373.
   PubMed Web of Science ®Google Scholar
• Rönnqvist I, Nilsson FK, Nordenskjöld A. Electroconvulsive therapy and the risk of suicide in hospitalized patients with major depressive disorder. JAMA Netw Open. 2021;4(7):e2116589.
   PubMed Web of Science ®Google Scholar
• Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the consortium for research in electroconvulsive therapy (CORE). Arch Gen Psychiatry. 2006;63(12):1337–1344.
   PubMed Web of Science ®Google Scholar
• Hirschowitz J, Kolevzon A, Garakani A. The pharmacological treatment of bipolar disorder: the question of modern advances. Harv Rev Psychiatry. 2010;18(5):266–278.
   PubMed Web of Science ®Google Scholar
• Undurraga J, Sim K, Tondo L, et al. Lithium treatment for unipolar major depressive disorder: Systematic review. J Psychopharmacol. 2019;33(2):167–176.
   PubMed Web of Science ®Google Scholar
• Lambrichts S, Detraux J, Vansteelandt K, et al. Does lithium prevent relapse following successful electroconvulsive therapy for major depression? A systematic review and Meta-analysis. Acta Psychiatr Scand. 2021;143(4):294–306.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.
   PubMed Web of Science ®Google Scholar
• Coryell W. The treatment of psychotic depression. J Clin Psychiatry. 1998;59 Suppl 1:22–27. discussion 8–9.
   PubMed Web of Science ®Google Scholar
• Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a european multicenter study. J Clin Psychiatry. 2007;68(07):1062–1070.
   PubMed Web of Science ®Google Scholar
• Serra M, Gasto C, Navarro V, et al. [Maintenance electroconvulsive therapy in elderly psychotic unipolar depression]. Med Clin (Barc). 2006;126(13):491–492.
   PubMed Web of Science ®Google Scholar
• Snedkova LV. [A trial of the use of nifedipine for preventing relapses in affective and schizoaffective psychoses]. Zh Nevrol Psikhiatr Im S S Korsakova. 1996;96(1):61–66.
   PubMedGoogle Scholar
• Brus O, Cao Y, Hammar Å, et al. Lithium for suicide and readmission prevention after electroconvulsive therapy for unipolar depression: population-based register study. BJPsych Open. 2019;5(3):e46.
   PubMed Web of Science ®Google Scholar
• Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161(9):1537–1547.
   PubMed Web of Science ®Google Scholar
• Viktorin A, Lichtenstein P, Thase ME, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. 2014;171(10):1067–1073.
   PubMed Web of Science ®Google Scholar
• Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011;72(02):156–167.
   PubMedGoogle Scholar